Microcap Allurion Technologies (NYSE:ALUR) surged ~31% in after-hours trading Thursday after posting preliminary data on weight loss associated with its gastric balloon in combination with Novo ...

The combined treatment was tested on 52 patients, who showed an average total weight loss of 20.3% and an increase in lean body mass of 15% after 8 months. The Allurion Program includes a ...

The combined treatment was tested on 52 patients, who showed an average total weight loss of 20.3% and an increase in lean body mass of 15% after 8 months. The Allurion Program includes a swallowable ...

Average Total Weight Loss of 20% With 15% Increase in Lean Body Mass After 8 Months of Combined Therapy NATICK, Mass., March 20, 2025--(BUSINESS WIRE)--Allurion Technologies, Inc. ("Allurion" or ...

Shares of Allurion Technologies on Friday surged a ... of its gastric balloon in combination with a low dose of the weight-loss and type 2 diabetes therapy GLP-1. The stock was up 40% to $3. ...

And importantly, each of these issues is exacerbated when higher doses are needed to achieve clinically meaningful weight loss, which is the standard path. We believe that combining the Allurion ...

Allurion Technologies, Inc. ("Allurion" or the "Company") , a company dedicated to ending obesity, today announced that its Special Meeting of Stockholders (the "Special Meeting"), originally ...

Allurion is dedicated to ending obesity. The Allurion Program is a weight loss platform that features the Allurion Gastric Balloon, the world’s first and only swallowable, procedure-less ...

Allurion Technologies Inc. focuses on ending obesity with a weight loss platform to treat people who are overweight. Its platform, the Allurion Program, features swallowable and procedure-less ...

About Allurion Allurion is dedicated to ending obesity. The Allurion Program is a weight-loss platform that combines the Allurion Gastric Balloon, the world’s first and only swallowable ...